Acute cardiac care & resuscitation
Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial
Primary resultResult — go to the resultHazard ratio 0.56 95% CI 0.21–1.45- stopped early (COVID-19 pandemic)
Authors' conclusion
Due to the limited number of patients recruited to the trial, no definite conclusions could be drawn from the available data.
Study context
- Population
- Patients with persistent cardiogenic shock 30 minutes after primary PCI of the culprit lesion for acute myocardial infarction (MI)
- Participants
- 35 patients
- Comparison
- Venoarterial extracorporeal membrane oxygenation (VA-ECMO) vs standard therapy
- VA-ECMOn = 17
- Standard therapyn = 18reference
- Primary endpoint
- All-cause mortality
- Follow-up
- 30 days
Methodological detailsmulticentre, pan-European, Trial stopped before completion of recruitment due to the COVID-19 pandemic
- Multicentre
- pan-European
- Trial stopped before completion of recruitment due to the COVID-19 pandemic
Primary result
As reported in the abstract
Hazard ratio
0.56
95% CI 0.21–1.45
P = 0.22
By group
VA-ECMOvs Standard therapy
HR 0.56 (95% CI 0.21–1.45); P = 0.22
Secondary outcomes
| Outcome | VA-ECMO | Standard therapy | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| All-cause mortality · 1 year | 51.8% | 81.5% | 0.52 (0.21–1.26) | P = 0.14 | |
| 0.20.5125Hazard ratio (log scale) |
Safety
Vascular complications
Bleeding complications
Original publication
Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial. EuroIntervention. Published 21 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →